Rationale: Congenital hyperinsulinism (CHI) is the most common cause of persistent hypoglycemia in infancy that can cause permanent brain damage. Consequently, optimal management is extremely important. Current pharmacologic and surgical treatment were available that included diazoxide and octreotides.
Introduction
Congenital hyperinsulinism (CHI) is a rare disease characterized by persistent hypoglycemia accompanied by inappropriately elevated circulating insulin concentration. [1] The worldwide estimated incidence is 1 in 50,000 live births. In Saudi Arabia, the incidence is 1 in 2675 live births, with 51% of them having parents who were first or second cousins. [2] CHI is caused by mutations in the gene responsible for the regulation of the release of insulin, which is produced by the beta cells of pancreas. Mutations in at least 9 genes have been found to cause CHI with ABCC8 gene mutations being the most common.
[3] Current pharmacologic treatments are available that include diazoxide. However, in cases with diazoxide unresponsiveness, alternative medical and surgical approaches may be required to decrease the risk of hypoglycemia. [4] Octreotide, a somatostatin analog, often has a role in the management of those children. It acts on the somatostatin receptors SSTR2 and SSTR5 with inhibition of secretions of a variety of hormones, including insulin. [5] Octreotide has been used for nearly 20 years for both short and long-term control of diazoxide-unresponsive CHI patients. [5] Octreotides have a variety of adverse effects, including a dosedependent reduction in splanchnic blood flow [4] and an increase in the risk of bacterial and rarely viral infections. All the aforementioned drawbacks of Octreotides contribute to the pathogenesis of necrotizing enterocolitis (NEC). NEC is a serious condition affecting mostly preterm infants with high mortality Editor: Oliver Schildgen.
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All data generated or analyzed during this study are included in this published article. rates owing to the fact that it results in both inflammation and bacterial invasion of the bowel wall. [6, 7] We report a Saudi male infant with homozygous deletion of the ABCC8 gene of CHI who had diazoxide-unresponsiveness and was treated with Octreotides preceded by a nearly total pancreatectomy, which precipitated him to NEC in association with ROTA virus infection.
Patient's presentation
Our patient is a Saudi term male infant who was a product of consanguinity marriage of first-degree cousins. His mother had an uneventful pregnancy. He was born by spontaneous vaginal delivery and was large for his gestational age. His APGAR score of 6 (2 points for the heart rate 123/min, 1 point for his irregular breathing, 1 point for his extremities blue color, 1 point for his weak tone and 1 point for his reflexes) and 8 (2 points for the heart rate 143/min, 1 point for his irregular breathing, 2 points for his pink color, 2 points for his activity and 1 point for the reflexes) at 1 and 5 min. Within few minutes, he started to develop respiratory distress and was admitted to the neonatal intensive care unit (NICU) with initial capillary blood gas of pH: 7.44, PCO 2 : 42, PO 2 :44, and HCO 3 : 28.
While being treated in NICU with noninvasive ventilation, he started to suffer from frequent attacks of supraventricular tachycardia (SVT), which was very difficult to treat with failure of adenosine infusion of 250 mg/kg and was finally controlled by DC cardioversion and Amidarone infusion of 5 mg/kg followed by maintenance infusion. Moreover, he was then shifted to Esmolol 100 mcq/min and Propranolol 1 mg/kg/dose/6 hours. Echocardiogram revealed septal hypertrophy and pulmonary stenosis.
After 2 hours of birth, not only did the baby had low blood glucose level that was down to 0.7 mmol/L, but he also suffered from frequent hypoglycemic episodes that were characterized by persistency and difficulty to control despite Dextrose 10% boluses and high glucose infusion rate reaching up to 25 mg/kg/min which raised the attention for the possibility of hyperinsulinism. Even though Diazoxide has been given with a maximum dose of 15 mg/ kg/day, no response has been documented. As an aftermath, the patient started on Octreotide 20 mg/kg/day. Professional help by an Endocrinologist was sought who advised to send for serum critical sample for insulin, C-peptide, nonesterified free fatty acids, and adrenocorticotropic hormone (ACTH). It came out with very high insulin level of 2280.0 pmol/L (17.8-173 pmol/L) and very high C peptide of 7.19 pmol/L (0.37-1.47 pmol/L), while nonesterified free fatty acids and ACTH were normal. Not to mention the fact that the urine was negative for ketone bodies. After a gene study for CHI has been sent, homozygous deletion of ABCC8 exons 1-22 was revealed documenting the diagnosis of CHI.
At the age of 1 month after failure of medical therapy to control his hypoglycemic attacks, near total pancreatectomy with resection of up to 95% of his pancreas was done.
Frequent attacks of hypoglycemia have been documented after the operation, which were controlled by octreotide dose of 30 mg/kg/day. At the age of 4 months, the patient was readmitted with abdominal distention, vomiting, and bloody diarrhea and was diagnosed as acute hemorrhagic gastroenteritis complicated with NEC. Not only did a positive abdominal X-ray uncover a suggestion of NEC (Fig. 1) but also isolated Rota virus was identified in a stool sample. Medical management was initiated with meropenem, metronidazole, and targocid with nothing per oral for 2 weeks. Total parenteral nutrition (TPN) was started and no surgical intervention has been required. He was discharged after 1 month with good condition, but delayed developmental milestones have been observed with neither being able to focus his eyes nor to support his head or roll over supine to prone position. He was not able to sit at the age of 7 months, nor able to stand or say any word at the age of 10 months.
Auditory assessment revealed bilateral sensorineural hearing loss. On the contrary, ophthalmology examination was normal.
Magnetic resonant imaging was done and showed cystic hygroma with thin corpus callosum (Fig. 2) .
Our patient is currently 10 months old with multidisciplinary care and follows-up by pediatric endocrinologist, neurologist, gastroenterologist, and clinical nutritionist.
Discussion
CHI (MIM; 256450) is a heterogeneous disease with hyperinsulinemic hypoglycemia. Most frequently, the disorder is caused by a mutation in the ABCC8 gene (600508), [8] which encode the SUR1 subunit of the pancreatic beta cell potassium channel, on chromosome 11p15. [2] Other known etiologies include inactivating mutation of KCNJ11, HNF4A, HNF1A, HADH, and UCP2-activating mutations of GLUD1, GCK, and SLC16A1. [5] Severe hypoglycemia in infancy can cause permanent brain damage; therefore, optimal management is extremely important [5] including Diazoxide or octrotide as an alternative, for those unresponsive to diazoxide.
Octreotide is a somatostatin analogue that was used for the first time in the treatment of CHI in 1986. Since then, it is commonly used in the management of CHI. Despite the fact that the medication has a wide variety of potential adverse reactions, octreotide is generally well tolerated. It has been extensively demonstrated that octreotide reduces the splanchnic blood flow in dose-dependent manner; as a result, not only does it affect the entire gastrointestinal tract, [9] but it also contributes to the development of NEC which seems to be not dose dependent as NEC wasn't reported in a cohort 28.
Patients with CHI receiving high dose of octreotide up to 30 m g/kg, [10] on the contrary, NEC had developed in patients on relatively lower doses of 8 mg/kg/day in coexistence of other risk factors like total anomalous pulmonary venous connection, coarctation of the aorta , others. [4, 9, 11] It is likely that NEC in patients receiving octreotides needs an association needs coexisting other risk factors. For instance, our patient developed NEC in association with Rota virus as an additional risk factor. Although several outbreaks of NEC associated with Rota virus have been described previously in neonates in NICU, [12] no cases in term infants have been reported.
We believe that our patient is the first case reported in term infant with CHI on Octreotide therapy to develop NEC in association with Rota virus.
We also suspect that our patient suffers Usher-CHI syndrome owing to the fact that CHI is associated with symptoms of Usher syndrome, that is, hearing loss and childhood-onset retinitis pigmentosa. [8] This association is caused by a homozygous contiguous deletion, including USH1C (605242), ABCC8 (600509), and KCNJ11 (600937) on chromosome 11p15-p14 (MIM: 606528). [13] 
